Retatrutide is a first-in-class triple hormone receptor agonist developed by Eli Lilly that targets GIP, GLP-1, and glucagon receptors simultaneously. With Phase 2 results showing up to 24.2% body weight reduction at 48 weeks and Phase 3 data demonstrating up to 28.7% weight loss at 68 weeks, it is generating enormous interest as a next-generation weight management treatment.
But what about retatrutide side effects? Every effective medication carries risks, and understanding those risks is essential for making informed decisions. This article provides a thorough, evidence-based analysis of retatrutide side effects drawn from published clinical trial data, including the Phase 2 trial published in the New England Journal of Medicine (Jastreboff et al., 2023) and the Phase 3 TRIUMPH-4 trial results presented in December 2025.
Key Takeaways
- Gastrointestinal side effects are the most common, with nausea affecting up to 60% of participants at the highest dose (12 mg) in Phase 2 trials, though most cases are mild to moderate and occur during dose escalation.
- Dysesthesia (tingling, altered skin sensation) is a unique finding that many sources overlook — it affected 20.9% of participants at 12 mg in Phase 3 trials and appears linked to the drug's glucagon receptor activity.
- Heart rate increases of approximately 5–10 beats per minute have been observed, peaking at week 24 and declining thereafter.
- Serious adverse events occurred at comparable rates in retatrutide and placebo groups (4% in each) during Phase 2 trials.
- Gradual dose escalation significantly reduces side effect severity — participants who skipped titration experienced nearly double the GI symptom rates.
- Regular blood testing for liver enzymes, pancreatic markers, kidney function, and thyroid hormones is recommended during treatment.
Overview of Retatrutide's Safety Profile
Retatrutide's safety profile has been characterised across multiple clinical trials. The Phase 2 trial enrolled 338 adults with obesity (BMI of 30 or higher, or 27 or higher with at least one weight-related condition) and randomised them to receive weekly subcutaneous injections of retatrutide at doses ranging from 0.5 mg to 12 mg, or placebo, over 48 weeks.
Overall adverse events during the treatment period were reported in 70% of participants in the placebo group and 73% to 94% in the retatrutide groups, with the highest incidence observed at the 8 mg and 12 mg doses. However, the rate of serious adverse events was 4% in both placebo and retatrutide arms, indicating that while side effects were more frequent with the drug, they were predominantly mild to moderate in nature.
The Phase 3 TRIUMPH-4 trial, which enrolled 445 adults with obesity or overweight and knee osteoarthritis, confirmed and extended these findings at the 9 mg and 12 mg maintenance doses over 68 weeks. Importantly, it also identified a new safety signal — dysesthesia — that had not been prominent in the earlier Phase 2 data.
What sets retatrutide apart from other incretin-based therapies is its triple receptor mechanism. By activating glucagon receptors in addition to GLP-1 and GIP receptors, it introduces a side effect profile that partially overlaps with semaglutide and tirzepatide but also includes effects that are unique to this drug class.
Common Retatrutide Side Effects by Dose
A clear dose-response relationship exists for most retatrutide side effects. The following table summarises the incidence of common adverse events reported in the Phase 2 trial (Jastreboff et al., NEJM 2023), which tested multiple dose levels with gradual escalation:
| Side Effect | Placebo | 1 mg | 4 mg | 8 mg | 12 mg |
|---|---|---|---|---|---|
| Nausea | 11% | 14% | 36% | 44% | 60% |
| Diarrhoea | 11% | 9% | 20% | 20% | 15% |
| Vomiting | 1% | 3% | 12% | 12% | 26% |
| Constipation | 3% | 7% | 15% | 11% | 16% |
| Decreased appetite | 3% | 5% | 9% | 11% | 14% |
| Injection site reactions | 0% | 1% | 5% | 7% | 8% |
| Dysesthesia* | 0.7% | — | — | 8.8% | 20.9% |
*Dysesthesia rates from Phase 3 TRIUMPH-4 trial (9 mg and 12 mg arms). Phase 2 reported cutaneous hyperesthesia and skin sensitivity in approximately 7% of retatrutide participants vs. 1% placebo.
Two patterns emerge from this data. First, most side effects show a clear dose-dependent increase. Second, the gap between low-dose and high-dose groups is substantial — nausea, for example, jumps from 14% at 1 mg to 60% at 12 mg. This underscores the importance of gradual dose escalation, which we discuss in detail below.
Gastrointestinal Side Effects in Detail
Gastrointestinal side effects are the hallmark adverse events of all incretin-based therapies, and retatrutide is no exception. In the Phase 3 TRIUMPH-4 trial, 43% of participants reported nausea, 33% experienced diarrhoea, and 21% had vomiting. Here is what the data tells us about each.
Nausea
Nausea is the single most commonly reported retatrutide side effect. In the Phase 2 trial, rates ranged from 14% at 1 mg to 60% at 12 mg. Importantly, the meta-analysis by Alshehri et al. (2024) found that the relative risk of nausea was 2.69 at 4 mg, 4.27 at 8 mg, and 4.00 at 12 mg compared to placebo — a pattern suggesting the sharpest increase occurs between 4 mg and 8 mg.
There is encouraging evidence that nausea is largely transient. Most episodes occurred during dose escalation periods (the first 1–2 weeks at each new dose level) and resolved without intervention. The Phase 2 trial also demonstrated that starting at 2 mg rather than 4 mg significantly reduced nausea incidence, even when participants ultimately reached the same maintenance dose.
Vomiting
Vomiting followed a similar dose-dependent pattern, rising from 3% at 1 mg to 26% at 12 mg in Phase 2 data. The meta-analysis showed that vomiting had the steepest relative risk of any GI side effect, with a relative risk of 8.98 at 12 mg compared to placebo. While most episodes were mild to moderate, vomiting was a contributing factor in some treatment discontinuations, particularly at higher doses.
Persistent vomiting requires medical attention because of the risk of dehydration and electrolyte imbalances, which can secondarily affect kidney function. This is one reason why regular blood monitoring during treatment is advisable.
Diarrhoea
Diarrhoea affected 9% to 20% of participants across dose groups in Phase 2, and 33% in the Phase 3 TRIUMPH-4 trial. Interestingly, diarrhoea rates in Phase 2 did not follow the same strictly linear dose-response as nausea — the 4 mg group and 8 mg group both reported 20%, while the 12 mg group reported 15%. This may reflect individual variation in gut adaptation or the protective effect of slower dose escalation at higher doses.
Constipation
Constipation affected 7% to 16% of participants across dose groups. While less attention-grabbing than nausea or vomiting, constipation is worth monitoring because it can persist beyond the escalation phase and may require dietary adjustments such as increased fibre and fluid intake.
When Do GI Side Effects Peak?
The consistent finding across retatrutide trials is that gastrointestinal side effects are worst during dose escalation and improve at stable maintenance doses. Most participants who experienced GI symptoms found them tolerable after the initial adjustment period. This pattern mirrors what has been observed with semaglutide and tirzepatide and reflects the body's gradual adaptation to incretin receptor activation.
Dysesthesia: The Unique Side Effect Most Sources Miss
The Phase 3 TRIUMPH-4 trial revealed dysesthesia as a significant and dose-dependent finding that distinguishes retatrutide from other weight management medications. At the 12 mg dose, 20.9% of participants experienced dysesthesia, compared to 8.8% at 9 mg and just 0.7% in the placebo group. This is a side effect that many online sources about retatrutide overlook or underemphasise, yet it affects roughly 1 in 5 patients at the highest dose.
Why Does Retatrutide Cause Dysesthesia?
The mechanism is not yet fully established, but researchers have proposed two leading hypotheses. The first centres on GLP-1 receptor activity on peripheral nerves, which may alter nerve signalling and produce abnormal sensory perceptions. The second hypothesis points to effects on small blood vessels that supply sensory nerves. Retatrutide's additional glucagon receptor agonism — which neither semaglutide nor tirzepatide possess — may be a contributing factor, as glucagon receptors are expressed in nervous system tissue.
It is worth noting that dysesthesia has also been reported at lower rates with high-dose oral semaglutide, suggesting that GLP-1 receptor activity at sufficient intensity may itself contribute to this effect. However, the substantially higher rates with retatrutide point to the glucagon receptor component as an amplifying factor.
Severity and Duration
The reassuring finding is that dysesthesia events in the TRIUMPH-4 trial were generally classified as mild. They rarely led to treatment discontinuation, and current evidence does not suggest they are associated with long-term nerve damage. However, given that this is a relatively new finding, longer-term surveillance will be important to confirm its benign nature.
The Phase 2 trial had previously reported cutaneous hyperesthesia (heightened skin sensitivity) in approximately 7% of retatrutide participants compared to 1% of those receiving placebo, with none of these events classified as severe or serious, and none leading to treatment discontinuation. The higher rates seen in Phase 3 likely reflect the larger sample size and longer treatment duration.
Heart Rate Changes
Retatrutide has been associated with dose-dependent increases in resting heart rate, a finding consistent with other GLP-1 receptor agonists but notable in its magnitude. In the Phase 2 trial, heart rate increases peaked at approximately week 24 before gradually declining toward baseline by weeks 36 to 48.
The largest average heart rate increase was approximately 6.7 beats per minute at the 12 mg dose, with a typical range of 5–10 bpm across higher dose groups. While modest, these increases warrant attention for individuals with pre-existing cardiac conditions.
Cardiac arrhythmias were reported in 2–11% of participants receiving retatrutide, compared to 2% in the placebo group. However, these were not classified as serious events. Supraventricular arrhythmias and cardiac conduction disorders were noted in a small number of participants, and no increase in heart attacks or major adverse cardiovascular events has been reported to date.
It is important to note that Phase 3 cardiovascular outcome data are not yet available for retatrutide. Dedicated cardiovascular outcome trials will be required before a definitive safety assessment can be made for patients with established heart disease.
Serious Adverse Events
In the Phase 2 trial, 15 serious adverse events were reported in 13 participants, with a frequency of 4% in both the retatrutide and placebo groups. This parity suggests that the serious events observed were not causally related to the drug.
Key findings on specific serious adverse events include:
- Acute pancreatitis: One case was reported at the 12 mg dose. Increases in amylase and lipase levels (pancreatic enzymes) were observed but were asymptomatic in all other cases. Pancreatitis is a known class-effect concern for all incretin-based therapies and remains under close surveillance.
- Gallbladder events: A small number of gallbladder-related events were reported, but at rates comparable to placebo. Rapid weight loss itself is an independent risk factor for gallstone formation, complicating the attribution of these events to the drug specifically.
- Allergic reactions: Allergic or hypersensitivity reactions occurred in 3–13% of the retatrutide group compared to 3% in the placebo group. The majority were mild.
- Liver enzymes: Transient increases in ALT (alanine aminotransferase) to more than three times the upper limit of normal occurred in 1% of retatrutide participants. Mean ALT and AST levels were unchanged or had decreased by week 48, suggesting these elevations resolve over time.
In Phase 3, discontinuation rates were 12.2% at 9 mg and 18.2% at 12 mg, compared to 4% with placebo. Notably, some of these discontinuations were attributed by Eli Lilly to "perceived excessive weight loss" rather than adverse events, which complicates interpretation of the dropout rates as a purely safety-related measure.
Retatrutide vs Semaglutide vs Tirzepatide: Side Effect Comparison
One of the most common questions about retatrutide concerns how its side effect profile compares to the two incretin-based therapies already approved for weight management. The following table draws on published clinical trial data for each drug at its highest approved or studied dose. Note that no head-to-head trials have been conducted between retatrutide and the other two drugs, so these comparisons are cross-trial and should be interpreted with caution.
| Side Effect | Retatrutide 12 mg | Semaglutide 2.4 mg | Tirzepatide 15 mg |
|---|---|---|---|
| Nausea | 45–60% | ~44% | 22–33% |
| Vomiting | 21–26% | ~25% | 6–13% |
| Diarrhoea | 15–33% | ~30% | 13–22% |
| Constipation | 11–16% | ~24% | ~12% |
| Dysesthesia | 20.9% | Rare* | Not reported |
| Heart rate increase | 5–10 bpm | 1–4 bpm | 2–5 bpm |
| Max weight loss (trials) | 28.7% | ~17% | ~22% |
| Receptor targets | GIP + GLP-1 + Glucagon | GLP-1 | GIP + GLP-1 |
*Dysesthesia has been reported with high-dose oral semaglutide but not prominently with the injectable 2.4 mg formulation. Cross-trial comparisons have inherent limitations. Semaglutide data from STEP trials; tirzepatide data from SURMOUNT trials.
The key takeaway is that retatrutide has higher rates of nausea and vomiting than tirzepatide, comparable GI rates to semaglutide, and a unique dysesthesia signal that appears specific to its triple-agonist mechanism. However, it also delivers substantially greater weight loss — and the overall rate of serious adverse events is similar across all three drugs.
Track Your Health Biomarkers With a Blood Test
Monitor liver function, kidney health, and metabolic markers from home — whether you are on medication or simply want a baseline.
Core Health 45 Biomarkers Peak Insights 70 BiomarkersDose Escalation: How to Minimise Side Effects
Dose escalation is not merely a suggestion with retatrutide — it is a critical strategy for tolerability. The Phase 2 trial provided compelling evidence that gradual titration makes a substantial difference. When participants were assigned directly to 8 mg without titration, GI symptom rates nearly doubled compared to those who reached 8 mg through gradual escalation from a lower starting dose.
The Standard Escalation Protocol
In clinical trials, the typical dose escalation schedule for retatrutide follows this pattern:
| Weeks | Weekly Dose |
|---|---|
| Weeks 1–4 | 1 mg |
| Weeks 5–8 | 2 mg |
| Weeks 9–12 | 4 mg |
| Weeks 13–16 | 8 mg |
| Week 17 onwards | 12 mg (maintenance) |
Each dose step lasts a minimum of four weeks, giving the body time to adapt before increasing. Prescribers may extend any dose step if a patient is experiencing significant GI side effects, and some patients achieve effective results at maintenance doses below 12 mg.
Practical Strategies Supported by Trial Evidence
- Start low, go slow: The trial showed that beginning at 2 mg rather than 4 mg reduced GI side effects without compromising long-term weight loss outcomes.
- Stay at each dose for the full escalation period: Rushing to higher doses increases the likelihood of severe nausea and vomiting.
- Pause escalation if needed: If GI side effects are persistent, trial protocols allowed participants to remain at the current dose for an additional four weeks before attempting an increase.
- Hydration and dietary adjustments: Eating smaller meals, avoiding high-fat foods, and maintaining fluid intake can help manage GI symptoms during escalation.
Blood Tests to Monitor for Retatrutide Side Effects
Clinical trials routinely monitor a range of blood biomarkers to detect potential adverse effects. Whether you are considering retatrutide or already taking a weight management medication, regular blood testing provides objective data on how your body is responding. Here are the key areas to monitor and why they matter.
Liver Function Tests
Retatrutide clinical trials observed transient elevations in ALT (alanine aminotransferase) in approximately 1% of participants. While mean liver enzyme levels returned to normal or decreased by week 48, individual monitoring is essential — particularly for those with pre-existing liver conditions such as non-alcoholic fatty liver disease (NAFLD), which is common in people with obesity.
A comprehensive liver function test measures ALT, AST (aspartate aminotransferase), GGT (gamma-glutamyl transferase), alkaline phosphatase, and bilirubin. These markers collectively paint a picture of liver health and can flag problems early, before symptoms appear.
Pancreatic Enzymes
Given the single case of acute pancreatitis reported at the 12 mg dose and the observation of asymptomatic amylase and lipase elevations in some participants, monitoring pancreatic enzyme levels is prudent. Amylase and lipase are the two primary blood markers used to assess pancreatic health, and persistent elevations may warrant further investigation even in the absence of abdominal pain.
Kidney Function
Dehydration from nausea, vomiting, or diarrhoea can impair kidney function, making creatinine and eGFR (estimated glomerular filtration rate) important markers to track. Retatrutide is contraindicated in severe renal impairment (eGFR below 30 mL/min/1.73m²), and even mild kidney stress should prompt a conversation with your doctor about hydration and dose management.
Thyroid Function
All GLP-1 receptor agonists carry a precautionary warning relating to thyroid C-cell tumours observed in rodent studies. While this has not been observed in humans, thyroid function testing — including TSH, free T4, and free T3 — is recommended as part of a comprehensive monitoring strategy. Severe uncontrolled thyroid disorders are a contraindication for retatrutide use.
Additional Markers
A full metabolic panel is valuable for anyone on a weight management programme, particularly one involving significant caloric restriction or rapid weight loss. Markers to consider include:
- HbA1c and fasting glucose — to monitor blood sugar regulation, especially relevant for those with prediabetes or type 2 diabetes
- Lipid panel (total cholesterol, LDL, HDL, triglycerides) — retatrutide trials showed improvements in lipid profiles, and tracking these changes can help quantify cardiovascular benefit
- Full blood count — to identify any nutritional deficiencies that may develop with reduced caloric intake
- Vitamin D, B12, and iron — common deficiencies that can emerge during significant weight loss
Get a Baseline Before Starting Any Medication
Comprehensive at-home blood tests covering liver, kidney, thyroid, metabolic markers, and more. Results reviewed by a GP.
Core Health — 45 Biomarkers Peak Insights — 70 BiomarkersFrequently Asked Questions About Retatrutide Side Effects
What are the most common side effects of retatrutide?
The most common retatrutide side effects are gastrointestinal: nausea (up to 60% at 12 mg in Phase 2), diarrhoea (15–33%), vomiting (21–26%), and constipation (11–16%). Decreased appetite (14% at 12 mg) and injection site reactions (up to 8%) are also frequently reported. These side effects are dose-dependent and most common during dose escalation.
Does retatrutide cause tingling or numbness?
Yes. Dysesthesia, which includes tingling, burning, and abnormal skin sensitivity, was reported in 20.9% of participants at the 12 mg dose and 8.8% at the 9 mg dose in the Phase 3 TRIUMPH-4 trial. This is a side effect that distinguishes retatrutide from semaglutide and tirzepatide. The events were generally mild and rarely led to discontinuation.
How do retatrutide side effects compare to semaglutide?
Retatrutide and semaglutide have broadly similar rates of nausea and vomiting at their highest doses (approximately 44–60% nausea). However, retatrutide has notably higher rates of dysesthesia (20.9% vs. rare with injectable semaglutide) and greater heart rate increases (5–10 bpm vs. 1–4 bpm). Retatrutide also produces significantly more weight loss (up to 28.7% vs. ~17%).
How long do retatrutide side effects last?
Most gastrointestinal side effects are worst during the first 1–2 weeks at each new dose level during escalation and improve once a stable maintenance dose is reached. Heart rate increases peak around week 24 and decline toward baseline by weeks 36–48. The duration of dysesthesia varies, but cases in the clinical trials were generally transient.
Can retatrutide cause pancreatitis?
One case of acute pancreatitis was reported in the Phase 2 trial at the 12 mg dose. Asymptomatic increases in pancreatic enzymes (amylase and lipase) were also observed. While pancreatitis is a known class-effect concern for all incretin-based therapies, the overall rate with retatrutide has not been higher than expected. Monitoring pancreatic enzymes through blood testing is recommended.
Is retatrutide safe for the heart?
In clinical trials, dose-dependent heart rate increases of 5–10 bpm were observed, peaking at week 24. Cardiac arrhythmias were reported in 2–11% of retatrutide participants vs. 2% with placebo, but none were classified as serious. No increase in heart attacks or major cardiovascular events has been reported. However, dedicated cardiovascular outcome trial data are not yet available.
What blood tests should I take before starting retatrutide?
Before starting any weight management medication, a comprehensive blood test is advisable. Key markers include liver function (ALT, AST, GGT), kidney function (creatinine, eGFR), pancreatic enzymes (amylase, lipase), thyroid hormones (TSH, free T4, free T3), HbA1c, lipid panel, and full blood count. This establishes a baseline for monitoring throughout treatment. Lola Health's Core Health 45 or Peak Insights 70 tests cover these biomarkers.
Is retatrutide approved in the UK?
No. As of early 2026, retatrutide has not been approved by the MHRA for use in the United Kingdom or by the FDA in the United States. It remains an investigational drug in Phase 3 clinical trials. Eli Lilly is expected to submit for regulatory approval upon completion of the TRIUMPH trial programme.
References
- Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972
- Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial. Press release, December 2025.
- Alshehri AA, et al. Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2024.
- Allodynia and Dysesthesia Associated With Semaglutide and Tirzepatide. PMC. 2025.
At-Home Blood Testing
Check your levels from home
Professional phlebotomist visit. Doctor-reviewed results in 2-5 days. Track your health with comprehensive blood panels.
→45-70 biomarkers tested · Venous blood draw · From £130